Novartis' Kymriah & Gilead's Yescarta become first EU-approved CAR T therapies

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah (tisagenlecleucel) has been awarded marketing authorisation in the EU for the treatment of blood cancer. Its rival, Gilead/Kite Therapeutics’ Yescarta (axicabtagene ciloleucel) has also been authorised, marking the first approval of its kind in the region.

As CAR-T therapies, both are manufactured from immune cells derived from a specific patient’s body.

read more

More From BioPortfolio on "Novartis' Kymriah & Gilead's Yescarta become first EU-approved CAR T therapies"